The analyses of observational longitudinal studies involving concurrent changes in treatment and medical conditions present difficulties because of the multitude of directions of potential relationships: past medication influences current symptoms; past symptoms influence current medication; and current medication is associated with current symptoms. In the context of a long-term study of non-randomized pharmacological treatment of schizophrenic relapse, we present an analysis of bivariate discrete-time transitional data with binary responses in an attempt to understand the transitional and concurrent relationships between schizophrenia relapse and medication use. A naive analysis does not show any association between previous medication and current relapse. However, we provide evidence suggesting that current treatment may impact current relapse for those who have previously taken medication, but not for those who haven't taken medication in the past. When univariate models are specified to assess these associations, the bivariate nature of the problem requires a choice of which response, relapse or medication, should be the dependent variable. In this case, the choice of relapse or medication as a dependent variable does matter. Hence, our results derive from models where both relapse and medication are treated as dependent variables. Specifically, we specify a bivariate log odds ratio for current relapse and current medication use and a separate univariate logit component for each of these outcomes. Each of these components contains transitional associations with previous relapse and medication. Such models represent extensions of univariate transitional association models (e.g. Diggle et al. (1994) ) and correspond to bivariate transitional models (e.g. Zeger and Liang (1991) ). We incorporate changes in transitional associations into the full-data parametric model for final inference, and investigate if these temporal changes are due to learning effects or the impact of drop-out. We also perform residual analyses and sensitivity analyses in the context of missing data patterns.
INTRODUCTION
The statistical assessment of the efficacy of treatment prescribed to patients suffering from a chronic illness and undergoing frequent symptomatic relapses has been a recurrent conundrum in clinical research. Examples include schizophrenia and migraine. The specific methodological difficulties stem from the fact that, typically, medication is expected to prevent relapse of symptoms, but that medication is often prescribed as a consequence of a relapse. Both medication and relapse are usually reported simultaneously by the physician in charge. Thus, it is difficult to discern causal pathways from crosssectional associations. The cross-sectional association between current medication and current treatment may be negative, positive, or null according to the relative prevalence of two types of patients: those who have a past history of taking most of their medication and for whom effective medication should prevent relapses, and those who have a history of poor treatment observance and thus for whom medication is likely to follow relapse.
To elucidate such a relationship between schizophrenia relapse and medication use in a sample of previously diagnosed schizophrenic out-patients, we present an analysis of bivariate discrete-time transitional data consisting of binary responses. Specifically, the data are from a cohort study of 58 schizophrenic-diagnosed subjects, each of whom had at most 60 consecutive monthly determinations of anti-psychotic medication and schizophrenic relapse events. All patients, 28 males and 30 females with mean and median ages of 26.1 and 24 years, had been admitted to one of three units of a public psychiatric hospital from 1989 to 1991. Follow-up for each subject began after discharge with stabilized psychotropic pharmacological treatment. Follow-up periods ranged between 5 and 60 months because of both missed visits and drop outs from the study.
The two main outcomes analyzed for this study were relapse of schizophrenic episodes and whether or not medication was taken, each of which was determined monthly by study personnel. Each month, a patient was considered to have relapsed if (a) psychotic symptoms were observed after a symptomfree period of at least one month or (b) if persisting psychotic symptoms became markedly exacerbated. Monthly medication use was determined by clinician assessment and interviews with the patient. Of particular interest is the question of whether previous medication reduces the risk of current relapse. We show that the association between current medication and current relapse is stronger if medication was taken previously. In turn, it is inferred that consistent use of medication across time is most effective in reducing the risk of relapse.
The modeling approach used to derive this inference consisted of bivariate log odds ratio (OR) and univariate logit components with an emphasis on the bivariate log OR. As a reviewer notes, given that both medication and relapse are random outcomes, one could make the assessment by fitting one of two univariate models: (1) a logistic model with current relapse as the outcome and current and previous medication and their interaction as the independent variables; and (2) a logistic model with current medication as the outcome and current relapse and previous medication and their interaction as the independent variables. The interaction term in each model corresponds to the effect that previous medication has on the crosssectional OR between current medication and relapse. While these two analyses yield the same estimate, including a term such as the effect of relapse in the second previous month, which has a significant impact on the cross-sectional OR for our data, results in different estimates depending on which outcome, relapse or medication, is used. This ambiguity of which model to use in investigating the cross-sectional OR motivates the proposed bivariate model, for which no such decision needs to be made.
Furthermore, even if the association between current medication and current relapse and its dependence on previous outcomes were not of interest but a nuisance parameter, modeling the medication and relapse responses jointly with the proposed bivariate model would still be beneficial. This joint modeling approach yields more efficient estimates than modeling the two responses separately (McCullagh and Nelder, 1989, p. 229) .
We include in each of the three model components (two logit components and the log OR component) terms for previous medication, previous relapse, a time effect, and interactions of time with previous medication or relapse. This proposed approach represents an extension of the bivariate transition model discussed but not implemented by Zeger and Liang (1991) . We note that additional analyses with random effects included in the model, as in Ten Have and Morabia (1999), did not reveal any significant residual correlation within the longitudinal data due to inter-subject heterogeneity and beyond that accounted for by transitional associations involving current and previous medication and relapse. Under the assumption that the proposed transitional bivariate model is correct, the estimation procedure presented here is a maximum likelihood approach. Nonetheless, to protect against residual correlation apart from the transitional associations, we present robust standard errors based on the sandwich estimator. In addition, we present analyses of residuals and of sensitivity with respect to drop-out patterns.
The proposed model is developed in Section 2. The estimation procedure is addressed in Section 3. Assessing lack-of-fit is considered in Section 5.4. The proposed method with sensitivity analyses is then applied in Section 4 to the example dataset.
MODEL SPECIFICATION
Assume there are I independent subjects, and let T i denote the set of integer time points at which the paired binary responses of relapse and medication are observed for subject i.
For the hth (h = 1, 2) of the two responses for subject i at a given time j (∈ T i ), we define the binary random variable Y hi j , which equals one or zero for a positive or negative outcome, respectively. For relapse, Y 1i j = 1 if the corresponding response is a clinically diagnosed relapse during the jth month. For medication, Y 2i j = 1 if the subject is confirmed by a clinician to have taken medication during the jth month.
For subject's hth response variable, the univariate probability of a positive outcome for this response at time j is denoted as π hi j = Pr(Y hi j = 1), h = 1, 2. The corresponding joint probability is denoted by µ 11i j = Pr(Y 1i j = Y 2i j = 1). The model at time j is comprised of a logistic model for each univariate probability:
for h = 1, 2; and a log OR model for the bivariate association:
where
Here, x hi j , h = 1, 2, 3, are covariate vectors for the ith subject at time j; and β h , h = 1, 2, 3, are the parameter vectors. We assume Y 1i j and Y 2i j are independent of Y 1i j and Y 2i j for j = j given the covariates x hi j , j = 1, 2, 3, which in our data includes Y hi j , j = 1, 2 where j < j. More specifically, the parameter vectors, β h , h = 1, 2 for the marginal logit components contain log ORs respresenting the association between a particular covariate and the corresponding outcome Y hi j . The parameter vector β 3 contains differences in log ORs representing the modification of the cross-sectional OR between Y 1i j and Y 2i j by a particular covariate in X 3i j .
For the transitional schizophrenic data, the parameters in β h , h = 1, 2, 3 are transitional associations relating previous medication and relapse to current medication and relapse, time period effects, or the interactions between time period and the transitional associations. For the marginal logit parameters in β h , h = 1, 2, the transitional associations of interest are the log ORs between medication in the previous two months and current relapse; and the log ORs between relapse in the previous two months and current medication. We include other transitional associations that are statistically significant but of less interest such as the log OR between relapse in the previous two months and current relapse and analogous associations for medication. For the cross-sectional log OR between current relapse and current medication, the parameter of interest in β 3 is the modifying effect of this cross-sectional OR by medication in the previous month. Finally, in each of the components, we also include the first-versus-second 30 month period effect and its interactions with the transitional parameters of interest. In addition, we have fitted separate bivariate models to consecutive ten month windows to investigate whether the two 30 month periods are sufficient for accommodating temporal variation in transitional associations.
To accommodate the kth-order autoregressive characteristics of the proposed model, we start the follow-up period after the first k months, and delete as a current month those months for which data from one of the k previous months is not available. For example, under a second-order model (i.e. the current response is dependent on the previous two months' outcomes), if subject i were missing data for only the 20th month, (4, . . . , 19, 23, . . . , 60) .
ESTIMATION
Under the conditional independence assumption given previous medication and relapse outcomes in x hi j , the likelihood for subject i is
where y hi j is the observed value of Y hi j , taking on the value of one or zero. Based upon (3), we have µ 11i j as a function of η i j , π 1i j , and π 2i j :
We maximize the product of the i terms in (4) across the I subjects with respect to the β h parameters, using a quasi-Newton approach with first derivatives based upon (4). Standard errors were obtained with the robust sandwich estimatorΣ =Ĥ −1ŜĤ−1 , whereŜ = I i=1ŝ iŝ T i , and whereŝ i is the vector of estimated first derivatives or score vector for (4) with β h , h = 1, 2, 3 replaced by their respective maximum likelihood estimates, andĤ is the corresponding estimated Hessian. We implemented this estimation procedure in a Fortran program on a Sun Microsystems Sparc Ultra.
Initial values for the fixed-effects parameters in the univariate logit components may be obtained from separate logistic regressions for each of the two response variables under independence across time. We set the initial value for the intercept of the log OR component equal to one, and the remaining log OR component parameters equal to 0. The estimates from this estimation procedure appear to be robust to starting values.
Under correct specification of the model, the parameter and standard error estimates yielded by our estimation procedure are I 1/2 consistent given that the maximum number of time points per subject is constant. These estimators are still consistent under missing-at-random paired responses: i.e. if Y 1i j and Y 2i j are missing, the probability of missingness is not dependent on the unobserved values that would have been taken on by Y 1i j and Y 2i j had they been observed (Rubin, 1976) . We address this issue as it relates to the schizophrenic data in the Results section.
RESULTS
In this section, we first present descriptive results, plots of observed probabilities across time, and period-specific estimates of transitional association parameters to assess temporal trends, which may indicate effects of drop-out. The parameters of the proposed models for the complete data are then accordingly specified and estimated, followed by a discussion of lack-of-fit and sensitivity analyses based on comparisons of drop-out groups. Finally, clinical interpretations of the model parameters are provided.
Descriptive results
We first present results based on raw percentages corresponding to the three associations of interest in this paper, ignoring subject clustering: (1) previous month medication with current relapse; (2) previous month relapse with current medication; and (3) previous month relapse with the crossing of current medication and current relapse. For the first question, there is no association between previous medication and current relapse overall, as the proportion of current relapses among previously medicated subjects (0.064 = 79/1234) is approximately equal to the current relapse rate for previously non-medicated subjects (0.060 = 79/1322). In contrast, corresponding to the second hypothesis above, there appears to be a difference in current medication rates between previously relapsed subjects (0.55 = 83/151) and previously non-relapsed subjects (0.47 = 1135/2405). Finally for the third hypothesis, the crosssectional OR between current medication and current relapse computed for previously medicated subjects (0.73 = 72 × 77/(7 × 1078)) indicates an inverse association relative to the same OR among previously non-medicated subjects (4.74 = 14 × 1189/(65 × 54)). The subsequent model-based results, which are adjusted for clustering due to subject, address the significance and temporal nature of these different associations among different medication groups.
The observed proportions of subjects medicated and relapsing at each time point, plotted across time in the top half of Figure 1 , suggest that the temporal associations involving relapse and medication (indicated by diamonds and crosses, respectively) differed between the first and second 30 month periods after initiation of treatment. The period-specific results presented in the next section support this delineation. Given the absence of any population-wide intervention during the follow-up period, such temporal trends may be due to drop-out, which we attempt to assess in Section 5.5. We note that the drop-out proportion as indicated by the cumulative drop-out plot (step function) in Figure 1 increases substantially at the 30 month mark.
Because the third-order transitional associations did not come close to being significant, the models addressed below consist of transitional associations up to the second order (i.e. covariates in the model include at most the two previous responses). More specifically, the p-value exceeds 0.15 for the change in log-likelihood due to deleting third-order associations. Hence, observed responses at a given time are considered missing if the responses are missing at any one of the previous three times. Accordingly, the first two months of observations are treated as missing for each individual.
In terms of adjusting for potential confounders, we do not include age and sex effects in the models, because there was no statistical evidence of associations between these demographic variables and relapse and medication. Data on side effects and optional psycho-therapy were not recorded. It is doubtful that side effects would have acted as time-varying confounders as defined by Robins et al., 1999 , given that it is unlikely that schizophrenia relapse would directly cause subsequent side effects, and side effects would directly cause future relapse. Similarly, there is well-accepted evidence that psycho-therapy is not very effective in treating schizophrenia (e.g. Baldessarini, 1985) , and hence not likely to be a time-varying unmeasured confounder.
Temporal trends
To assess temporal trends in the proposed transitional associations that may be due to drop-outs and to assess the plausibility of the time effects and their interactions in the model for the full data, we fitted separate bivariate models for consecutive disjoint ten month windows. The results of this disjoint windowed approach are displayed in Figures 2 and 3 . The models underlying these plots are described in a technical report in addition to smoothed local likelihood estimates of time-varying coefficients (Aerts and Claeskens, 1997; Carroll et al., 1998) . The plots in Figures 2 and 3 show estimates for the selected parameters along with pointwise 95% confidence bars based upon robust standard errors. The wide confidence bars in the second 30 month period preclude any conclusion of statistical significance. Nonetheless, for parameters such as the 'Intercept' and 'Med −1' log OR component parameters in Figure 2 , the 10-month-specific estimates in the second 30 month period reveal a trend downward, suggesting that the second 30 month trends may be real in spite of the insufficient number of observations in this period. This downward trend after 30 months suggests possible effects due to drop-out. The number of subjects in the study dropped from 58 to 45 within the first 30 month period. In Section 4.5, we attempt to assess the impact of drop-out by analyzing only the completers. Figure 3 shows that the estimates of previous medication effects on current relapse for the relapse logit component hug the horizontal line at 0. This supports the idea that the direct influence of previous medication on the risk of current relapse is weaker than the indirect impact of previous medication on the association between current medication and relapse. Again, the confidence bars widen after 30 months.
Full data model specifications
In Table 1 , we present parameter estimates and standard errors for a variety of models relating to the complete data. The proposed bivariate model in (1) and (2), denoted as BIV1, is compared to two other bivariate models. We arrived at the BIV1 model by removing all parameters that were not significant from the bivariate model with all first-and second-order effects and their interactions with 30 month period. Each of these removed parameters corresponded to Wald chi-squares of 3 or less. The remaining parameters, resulting in BIV1, are listed in Table 1 .
Several alternatives to BIV1 are presented in Table 1 . The first of these alternatives, denoted as BIV2, is a population-average bivariate model that omits the second-order transition parameters (e.g. effect of medication in the second previous month). It assesses the sensitivity of the first-order transition estimates to the presence of second-order associations. The second alternative, BIV3, is a bivariate model that includes the same log OR component as BIV1, but assumes intercept-only specifications for the logit components in (1). The BIV3 model was fitted to assess the robustness of the log OR estimates under the population-averaged bivariate model to different specifications of the logit components. Results are also presented for two separate population-averaged logistic models (UNI1 and UNI2), one for each response variable to assess the robustness of the logit estimates under the bivariate model to different specifications of the log OR component including independence. The form of the UNI1 and UNI2 logistic models follows that of (1).
Goodness-of-fit
In Figure 1 , we compare the observed proportions of patients with medication and relapse separately at each month to the average (across all covariate patterns) of the estimates of the corresponding fitted values (π hit ) under the BIV1 model. There is good congruence between the observed and fitted proportions for medication, but less so for relapse. The plot of relapse fitted values seems to be flatter than the corresponding plot of observed values, especially toward the end of the 60 month period, where observed risk of relapse increases more sharply than the predicted risk. Adding separate parameters for the 45-60 month period to the BIV1 model (i.e. three periods) led to singularity problems with the Hessian, and did not improve the fit for the last 15 months. The only estimate for this later period with a relatively large magnitude corresponded to the relationship between current relapse and previous month relapse. In contrast, the estimates for this last 15 months involving the more interesting relationships such as the effect of previous medication on current relapse and the effect of previous medication on the cross-sectional medication-relapse association were relatively small. In addition to the above assessment of model fit with respect to marginal probabilities, we examined Pearson residuals based upon the joint probabilities of relapse and medication across time. For the ith subject at the jth month, we define the Pearson residual as (
is an indicator function, andμ 11i j is obtained by plugging an estimate of β into (5). Among the 2556 Pearson residuals, 99.6% were between −1.2 and 2.0, with the remaining nine residuals ranging from 2.0 to 2.5. Approximate uniformity is revealed in the spread of these residuals across time (plot not shown). This uniformity does not conform well to the temporal plots of parameter estimates in Figures 2 and 3 , which display a clear change in parameter estimates after 30 months. That is, the change in these estimates after 30 months appears not to be due to outliers.
Sensitivity of estimates to drop-outs
Drop-outs and intermittent missed visits occurred for this study, such that the number of observations per subject ranged between 5 and 60. Thirty-seven (63.8%) subjects completed the study; 13 (22.4%) dropped out before 30 months; and 8 (13.8%) dropped out after 30 months. It is possible that conditional on previous outcomes, some of the missed visits and drop-outs were dependent on the underlying schizophrenic state of the particular patient at the time of the missed visits (i.e. the missing data were informative). There was no external information as to whether this was the case. To indirectly evaluate this assumption, we assessed the dependency of the probability of drop-out on previously observed outcomes, using Cox regression of time to drop-out on two and one month previous medication and relapse outcomes. None of the previous months' outcomes is significantly associated with time to drop-out, although the relative increase in risk of drop-out due to previous month's relapse is 2.97 with an asymptotic 95% confidence interval of (0. 85, 10.29) . While this association is not statistically significant, most of the confidence interval suggests a positive association, thus indicating that there may be a dependence between drop-out and observed outcomes. In turn, it may suggest a relationship between the missing data process and unobserved outcomes.
To further assess whether the observed changes in transition parameters across time were due to dropout of subjects, we analyzed two groups of subjects with the BIV1 model or a variation of it: those subjects who did not drop out before 30 months (13 subjects) and those who dropped out after 30 months or completed the study (45 subjects). This analysis amounts to a pattern mixture analysis (Little, 1995) . The BIV1 model results for the post 30 month drop-outs and completers did not differ much from those based upon all of the subjects (biggest difference for significant parameters is no more than 10%). The model for drop-outs prior to 30 months, which excluded period effects, yielded model-based log OR's equal to 11.97 and 4.80 for those who medicated and those who didn't medicate in the previous month, respectively. In contrast, the analogous BIV1 model log OR's for all subjects were 0.083 and 1.27 for the first period. The cross-sectional associations between current relapse and medication are in the same direction for previously medicated and non-medicated subjects if they dropped out prior to 30 months, whereas this is not the case for the first period estimates for the whole sample. An additional comparison of the completers (37) with those who dropped out (21) indicated that this pattern was not maintained with the group of all drop-outs, as they exhibited a similar pattern to the completers. Hence, the above sensitivity analyses suggest that the BIV1 model results pertain more to those who remained in the study beyond 30 months than those who dropped out early.
Furthermore, the temporal trends shown in Figures 2 and 3 (particularly for the log OR 'Med −1' parameter) may not be due to the effects of drop-out, because the BIV1 period effects and interactions corresponding to these trends were observed for both the whole sample and completers. Hence, it may be that the strengthing of the associations, particularly the cross-sectional associations between medication and relapse for those who previously medicated, is due to a learning effect and/or increase in tolerance of the medication among those who didn't drop out before 30 months.
First-order versus second-order models
While there are some significant differences between the model with first-and second-order transitional associations (BIV1) and the model with only first-order associations (BIV2), inference for the crosssectional OR between current medication and relapse remains the same. More specifically, there are some substantial differences between the BIV1 and BIV2 models with respect to the marginal logit estimates such as those in the medication component for the 'REL −1 × T2 − T1' interaction and for the 'T2 − T1' main effect. In contrast, for the OR component, the primary effect of interest, 'MED −1 × T2 − T1' is still significant.
Bivariate model versus univariate models
The presence of a log OR component under the bivariate model impacts to some extent the estimates and standard errors of the logit components in Table 1 . Although there is general agreement between the BIV1 and UNI1 or UNI2 models with respect to analogous estimates and standard errors, there are some differences. The only substantial difference pertains to the contrast between BIV1 and UNI2 models with respect to the very non-significant 'Rel −1' parameter in the medication component. The next largest difference corresponds to the BIV1-UNI1 contrast in the 'Rel −2 T2 − T1' estimates in the relapse logit component, which is approximately 20% of the BIV1 estimate. These discrepancies conform to McCullagh and Nelder (1989, p. 228) , who suggest that such differences may be expected. Table 1 also illustrates the sensitivity of OR estimates to specification of the logit components. The relatively disparate OR estimates between the BIV1 and BIV3 models indicate that estimation of the OR component parameters is not very robust to specification of the logit components. Nonetheless, inference is not changed.
Model interpretation
In this section, inference is addressed in terms of the parameter estimates under BIV1 in Table 1 and corresponding Wald-based 95% confidence intervals reported in the ensuing text in parentheses. We first address the impact of previous medication and relapse on current medication and relapse in terms of the marginal logit models, and then the primary question of how previous medication impacts the association between current medication and relapse. Table 1 shows that the log OR estimates between previous month's relapse and current relapse and between previous month's medication and current medication are 3.03 (2.54, 3.52) and 4.67 (2.36, 6.97), respectively. Neither log OR significantly differs between the two 30 month time periods. Unlike the previous month associations, the second previous month associations with current response differ between the two 30 month time periods. The second previous month log OR for relapse is positive in the first 30 month period (0.90 (0.51, 1.30)) but negative in the second 30 month period (−2.81 (−4.54, −1.08)). For medication, the second month's previous response is not significantly associated with the current medication response in the first 30 month period (0.54 (−0.23, 1.32)), although in the second 30 month period it is positively associated (1.99 (1.26, 2.73)).
In terms of the cross-variable associations, including previous month's medication as a covariate in the logit component for current relapse yields a very weak log OR (−0.020 (−0.43, 0.47) ). First previous month relapse is a significant predictor of current medication, but only in the second 30 month period (1.55 (0.32, 2.78) ). In contrast, relapse in the second previous month is positively associated with current medication for the first 30 months (1.12 (0.23, 2.01)), but is negatively associated with current medication in the second 30 months (−1.29 (−2.60, 0.023)). Thus, on the basis of the marginal components of the bivariate model, previous medication does not appear to be effective in directly reducing the risk of current relapse.
In contrast, the log OR component indicates that previous month's mediation increases the likelihood of current medication being associated with no relapse. Moreover, medication in the previous month negatively impacted the association between current relapse and medication (−1.18 (−2.62, 0.27) and −4.20 (−5.84 , −2.56)) for both the first and second 30 month periods, respectively. This strengthening of the effect in the second 30 month period is supported by the 10 month window plots in Figure 2 .
Furthermore, we attempted to obtain alternate estimates of the effect of previous medication on this cross-sectional association by fitting separate univariate models described in the introduction with current relapse and then current medication as the dependent variables. The resulting analogous univariate estimates of the effect of previous month's medication on the cross-sectional log OR are −1.16 and −0.88 for relapse and medication as separate dependent variables, respectively, in the first period, and −4.11 and −4.02, respectively, for the second period.
Under the fully specified bivariate model in Table 1 (BIV1), the four cross-sectional ORs between current medication and current relapse are, 2(1) 1.09 (0.43, 2.79) for previous month's medication in first period, (2) 0.35 (0.10, 1.21) for previous month's medication in second period (3) 3. 54 (1.07, 11.73) for no previous month's medication in first period and (4) 23.50 (7.56, 73.28) for no previous month's medication in second period. The corresponding ORs based on the raw data are 1.18, 0.35, 2.41, and 22.16, respectively. Except for the third OR above, these model-based estimates are within 10% of the raw data estimates, and the trends are the same for the two sets of estimates.
The log OR component indicates that at least in the second 30 month period, current medication may be protective against relapse only among subjects who have medicated in the previous month, whereas among subjects who have not medicated in the previous month, current relapse is likely to have induced current medication. However, it is difficult to conclude causality, because the data do not allow us to determine the temporal relationship between current medication and current relapse within a given month. Nonetheless, the above causal conjectures are supported by the results for the marginal logit component for medication in Table 1 . These results suggest that previous relapse induces current medication, which conforms to the positive cross-sectional association observed for the group who did not medicate in the previous month. For those who did medicate in the previous month, the marginal logit results for medication as an outcome discount the possibility that lack of relapse induces medication in favor of the more plausible causal relationship that medication reduces the risk of relapse.
DISCUSSION
We have shown that bivariate transitional models for binary responses can be used to address some of the methodological difficulties in investigating the complex time dependence of medication for the treatment of chronic diseases. These models treat both medication and relapse as outcomes dependent on their histories with additional focus on how their cross-sectional association varies across time as a function of their histories. This modeling strategy provided some evidence that medication may protect against concurrent relapse when patients had been previously medicated (i.e. frequent medication), while medication was likely to be initiated due to concurrent relapse when patients had not been previously medicated (i.e. inconsistent medication). This pattern was more evident in the latter months of the study, as confirmed by period-specific estimates. These relationships were maintained under sensitivity analyses when early or all drop-outs were omitted, although these relationships did not hold so well among early drop-outs. Moreover, adding subject random effects to the population-average bivariate models did not alter the results substantially.
In conclusion, the efficacy of treatment prescribed to patients suffering from a chronic illness and undergoing frequent symptomatic relapses, such as schizophrenia, may not necessarily be detected using the usual, simple regression models. These models can lead to the paradoxical conclusion that current medication is not effective in preventing disease relapses, when in reality it may for a sub-group of subjects who regularly medicate.
